AEON vs. CMMB, LSTA, BFRG, LPCN, EDSA, LSB, UBX, BCTX, EGRX, and BIVI
Should you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Chemomab Therapeutics (CMMB), Lisata Therapeutics (LSTA), Bullfrog AI (BFRG), Lipocine (LPCN), Edesa Biotech (EDSA), Lakeshore Biopharma (LSB), Unity Biotechnology (UBX), BriaCell Therapeutics (BCTX), Eagle Pharmaceuticals (EGRX), and BioVie (BIVI). These companies are all part of the "pharmaceutical products" industry.
AEON Biopharma vs.
AEON Biopharma (NASDAQ:AEON) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, community ranking, valuation, media sentiment, institutional ownership, risk, earnings and dividends.
In the previous week, AEON Biopharma had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for AEON Biopharma and 1 mentions for Chemomab Therapeutics. AEON Biopharma's average media sentiment score of 0.81 beat Chemomab Therapeutics' score of 0.00 indicating that AEON Biopharma is being referred to more favorably in the media.
AEON Biopharma presently has a consensus target price of $360.00, indicating a potential upside of 88,788.89%. Chemomab Therapeutics has a consensus target price of $9.00, indicating a potential upside of 703.57%. Given AEON Biopharma's higher probable upside, research analysts plainly believe AEON Biopharma is more favorable than Chemomab Therapeutics.
AEON Biopharma's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.
AEON Biopharma has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 46.0% of Chemomab Therapeutics shares are owned by institutional investors. 7.0% of AEON Biopharma shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Chemomab Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Chemomab Therapeutics received 11 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 65.52% of users gave Chemomab Therapeutics an outperform vote.
Summary
AEON Biopharma and Chemomab Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get AEON Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AEON Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:AEON) was last updated on 4/21/2025 by MarketBeat.com Staff
Buy AEON Stock Free AEON Stock Alerts